Phenotype-dependent and -independent actions of rosuvastatin on atherogenic lipoprotein subfractions in hyperlipidaemia
Phenotype-dependent and -independent actions of rosuvastatin on atherogenic lipoprotein subfractions in hyperlipidaemia
复制标题
DOI：
10.1016/j.atherosclerosis.2003.08.025
复制
发表时间：
2003-12-01
期刊：
影响因子：
5.3
通讯作者：
Packard, CJ
中科院分区：
文献类型：
--
作者：
Caslake, MJ;Stewart, G;Packard, CJ
这项随机、双盲、安慰剂对照交叉研究评价了瑞舒伐他汀（40 mg/天，持续8周）对致动脉粥样硬化的含载脂蛋白B的脂蛋白亚组分的影响。根据血浆甘油三酯（TG）或低密度脂蛋白胆固醇（LDL-C）升高招募受试者，将其分为正常血脂（NTG，n = 13; TG < 2.0 mmol/l）和高血脂（HTG，n = 16; TG > 2.0 mmol/l）组。两组在LDL-C（NTG-60%; HTG-56%）、apoB（均-49%）、中密度脂蛋白（NTG-57%; HTG-54%）和LDL循环质量（NTG-52%，HTG-58%）方面观察到瑞舒伐他汀的相似降低（与安慰剂相比，所有P < 0.001），即，这些变化与表型无关。HTG相对于NTG在小密度LDL（LDL-III）浓度方面观察到反应的表型依赖性（NTG-44%，P = NS; HTG-69%，P < 0.001），极低密度脂蛋白，NTG-18%（P = NS）; HTG-46%（P < 0.01）;残粒样胆固醇（NTG-31%（P = NS）; HTG-48%（P < 0.05））。在NTG和HTG中，瑞舒伐他汀分别使胆固醇酯转移蛋白（CETP）降低33%和37%（均P < 0.001）;仅在HTG中观察到胆固醇酯转移活性降低（-59%，P < 0.001）。因此，除了降低LDL和apoB浓度外，瑞舒伐他汀还在很大程度上纠正了有致动脉粥样硬化脂蛋白表型倾向的受试者的TG和LDL异常。(C)2003爱思唯尔爱尔兰有限公司保留所有权利。
This randomised, double-blind, placebo-controlled crossover study evaluated the effects of rosuvastatin (40 mg/day for 8 weeks) on atherogenic apolipoprotein B-containing lipoprotein subfractions. Subjects, recruited based on raised plasma triglyceride (TG) or low-density lipoprotein cholesterol (LDL-C), were divided into normotriglyceridaemic (NTG, n = 13; TG < 2.0 mmol/l) and hypertriglyceridaemic (HTG, n = 16; TG > 2.0 mmol/l) groups. Similar reductions on rosuvastatin were observed for both groups in LDL-C (NTG -60%; HTG -56%), apoB (both -49%), intermediate-density lipoprotein (NTG -57%; HTG -54%) and LDL circulating mass (NTG -52%, HTG -58%) (all P < 0.001 versus placebo), i.e., these changes were phenotype independent. Phenotype dependency in response was observed in HTG relative to NTG in concentration of small dense LDL (LDL-III) (NTG -44%, P = NS; HTG -69%, P < 0.001), very-low-density lipoprotein, (NTG -18%, P = NS; HTG 46%, P < 0.01), and remnant-like particle cholesterol (NTG -31%, P = NS; HTG -48%, P < 0.05). Rosuvastatin reduced cholesteryl ester transfer protein (CETP) by 33% in NTG and 37% in HTG (both P < 0.001); a reduction in cholesteryl ester transfer activity (-59%, P < 0.001) was observed in HTG only. Rosuvastatin therefore, in addition to lowering LDL and apoB-concentrations, largely corrected the TG and LDL abnormalities in subjects who had the propensity to develop the atherogenic lipoprotein phenotype. (C) 2003 Elsevier Ireland Ltd. All rights reserved.